G
Guillermo Garcia-Manero
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1611
Citations - 52621
Guillermo Garcia-Manero is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Myelodysplastic syndromes. The author has an hindex of 108, co-authored 1411 publications receiving 43103 citations. Previous affiliations of Guillermo Garcia-Manero include Sapporo Medical University & University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies.
Guillermo Garcia-Manero,Raoul Tibes,Tapan M. Kadia,Hagop M. Kantarjian,Martha Arellano,Emily A. Knight,Hao Xiong,Qin Qin,Wijith Munasinghe,Lisa Roberts-Rapp,Peter Ansell,Daniel H. Albert,Brian Oliver,Mark D. McKee,Justin L. Ricker,Hanna Jean Khoury +15 more
TL;DR: Ilorasertib exhibited acceptable safety and pharmacokinetics at or below the recommended phase 2 dose, displayed evidence of dual Aurora kinase and VEGF receptor kinase inhibition, and activity in AML.
Journal ArticleDOI
Impact of aberrant DNA methylation patterns including CYP1B1 methylation in adolescents and young adults with acute lymphocytic leukemia
Courtney D. DiNardo,Vazganush Gharibyan,Hui Yang,Yue Wei,Sherry Pierce,Hagop M. Kantarjian,Guillermo Garcia-Manero,Michael Rytting +7 more
TL;DR: The results suggest aberrant methylation among AYA patients is frequent, and may provide a common pathogenic mechanism, and the inferior outcome identified with methylation of the cytochrome p450 gene CYP1B1, an enzyme involved in drug metabolism and steroid synthesis, warrants further investigation.
Journal ArticleDOI
Histone Deacetylases: Transcriptional Regulation and other Cellular Functions
TL;DR: The importance and need of a comprehensive book source for investigators and individuals with interest in epigenetic therapy of cancer, especially for those who want and need a condensed, well-referenced guide to the area of HDACs is strong.
Journal ArticleDOI
Interim Analysis of the Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML
Curtis Lachowiez,Marina Konopleva,Tapan M. Kadia,Naval Daver,Sanam Loghavi,Sa A. Wang,Maria Adeoti,Sherry Pierce,Koichi Takahashi,Nicholas J. Short,Koji Sasaki,Gautam Borthakur,Ghayas C. Issa,William G. Wierda,Naveen Pemmaraju,Guillermo Montalban Bravo,Alessandra Ferrajoli,Nitin Jain,Lucia Masarova,Musa Yilmaz,Elias Jabbour,Guillermo Garcia-Manero,Steven M. Kornblau,Farhad Ravandi,Hagop M. Kantarjian,Courtney D. DiNardo +25 more
TL;DR: Assessment of the safety and tolerability, and determination of dose limiting toxicities and the maximal tolerated dose of FLAG-IDA with VEN (FLAG-IDA-VEN) proved effective in young, fit AML patients and indicated improved responses may be possible when used in combination with FLag-IDA.
Journal ArticleDOI
Chemoimmunotherapy with Cyclophosphomide, Fludarabine, Alemtuzumab and Rituximab (CFAR) Is Effective in Relapsed Patients with Chronic Lymphocytic Leukemia (CLL).
Xavier Badoux,Michael J. Keating,Susan O'Brien,Tapan M. Kadia,Alessandra Ferrajoli,Stefan Faderl,Charles Koller,Guillermo Garcia-Manero,Jan A. Burger,William G. Wierda +9 more
TL;DR: A long-term follow-up of 80 pts who received CFAR as salvage therapy demonstrated favorable responses in pts younger than 70 years with F-sensitive disease who had 5 or fewer prior therapies and CFAR is a good salvage regimen for pts who have received prior FC or FN based regimen.